Concepedia

Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients

M Kamal, Rehab H. Werida, Mahasen A. Radwan, Safaa Ragab Askar, Gamal A. Omran, Marwa Adham El-Mohamdy, Radwa Samir Mohamed Hagag

Inflammopharmacology · 2024 · 11 citations · 14 references

DOIFull text

Open access

Abstract

This study is registered on ClinicalTrials.gov under the identifier NCT05291039. (You can access the study at https://clinicaltrials.gov/study/NCT05291039 (First Posted: March 22, 2022).

References

14

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications

Christian Maaser, Andreas Sturm, Stephan R. Vavricka et al. · Journal of Crohn s and Colitis · 2018 · 1.7K citations · Full text

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects

Andreas Sturm, Christian Maaser, Emma Calabrese et al. · Journal of Crohn s and Colitis · 2018 · 435 citations · Full text

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab

Waqqas Afif, Jonathan A. Leighton, Stephen B. Hanauer et al. · Inflammatory Bowel Diseases · 2009 · 129 citations · Full text

Adalimumab safety in global clinical trials of patients with Crohnʼs disease

Jean–Frédéric Colombel, William J. Sandborn, Remo Panaccione et al. · Inflammatory Bowel Diseases · 2009 · 123 citations

Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs

Kristian Thorlund, Eric Druyts, Kabirraaj Toor et al. · Expert Review of Gastroenterology & Hepatology · 2015 · 59 citations